Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AIM Vaccine Co., Ltd. (6660.HK)
Beijing, CN
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.89% | -0.42% | -27.47% | -29.22% | -26.79% | -37.67% | -95.49% | -85.89% | -85.89% | -85.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-9.3% Q4'25: +0.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-139.1% Q4'25: +49.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-19.6% Q4'25: -3.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-17.8% Q4'25: -11.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-4.8% ★ Q4'25: -6.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.1% ★ Q4'25: +1.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-19.65× Q4'25: -19.41× (vs Q4'23)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.26B
est: 1.00B (+25.9%)
|
1.19B
est: 1.59B (-25.2%)
|
1.29B
est: 1.25B (+3.1%)
|
1.17B
est: 1.32B (-11.6%)
|
3.82B
3.82B – 3.82B
+189.9% YoY
|
5.56B
5.56B – 5.56B
+45.7% YoY
|
| EBITDA |
-242.03M
est: -321.08M (+24.6%)
|
-2.05B
est: -507.85M (-304.1%)
|
-98.83M
est: -407.01M (+75.7%)
|
-89.41M
est: -430.38M (+79.2%)
|
-1.25B
-1.25B – -1.25B
-189.9% YoY
|
-1.82B
-1.82B – -1.82B
-45.7% YoY
|
| EBIT |
-408.47M
est: -413.75M (+1.3%)
|
-2.23B
est: -654.43M (-240.3%)
|
-229.92M
est: -513.50M (+55.2%)
|
-207.87M
est: -542.99M (+61.7%)
|
-1.57B
-1.57B – -1.57B
-189.9% YoY
|
-2.29B
-2.29B – -2.29B
-45.7% YoY
|
| Net Income |
-319.60M
est: -71.81M (-345.0%)
|
-1.30B
est: 194.63M (-768.5%)
|
-277.23M
est: -256.91M (-7.9%)
|
-675.46M
est: -36.70M (-1,740.5%)
|
761.57M
761.57M – 761.57M
+2,175.1% YoY
|
1.52B
1.52B – 1.52B
+100.0% YoY
|
| SGA |
943.92M
est: 747.68M (+26.2%)
|
748.29M
est: 1.18B (-36.7%)
|
825.40M
est: 927.94M (-11.1%)
|
776.80M
est: 981.22M (-20.8%)
|
2.84B
2.84B – 2.84B
+189.9% YoY
|
4.14B
4.14B – 4.14B
+45.7% YoY
|
| EPS |
-0.31
est: -0.06 (-428.3%)
|
-1.07
est: 0.16 (-772.8%)
|
-0.23
est: -0.21 (-9.6%)
|
-0.55
est: -0.03 (-1,734.1%)
|
0.62
0.62 – 0.62
+2,175.1% YoY
|
1.24
1.24 – 1.24
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 52.3K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.00% | 5.8K | 0.59% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 51.6K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 17.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yan Zhou | Executive Chairman & Chief Executive Officer | 3M | male |
| Shaojun Jia | President & Executive Director | 2M | male |
| Wen Guan | Executive President & Executive Director | 2M | male |
| Xin Zhou | Executive Vice-Chairman & Executive President | 2M | male |
| Jie Zhou | Executive Director & Executive President | 859.8K | male |
| Fan Zhang | Chief Research Officer | — | male |
| Lixin Niu | Chief Financial Officer | — | female |
| Wenjuan Zhou | Chief Public Affairs Officer | — | female |
| Ling Liu | Secretary & Chief Investment Officer | — | female |
| Li Meng | Chief Quality Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6660.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
